Borgeson Blake sold $242K of RXRX

Recursion Pharmaceuticals (RXRX) stock rose 4.26% on optimism over AI-driven drug advances. The company reported positive Phase 1b/2 trial results for REC-4881 and early Phase 1 data for REC-1245. Sanofi optioned a candidate, triggering a $10M milestone. RXRX raised $200M, extending its cash runway. The stock has high volatility, trading at a 43x P/S ratio with negative margins.

Recursion Pharmaceuticals Inc. (RXRX) stock rose 3.85% on AI-driven drug discovery progress and institutional buying. The company reported positive Phase 1b/2 data for REC-4881 and REC-1245, and Sanofi exercised an option on an inflammatory candidate, triggering a $10M milestone. RXRX raised $200M in a follow-on offering, and ARK Investment Management has been accumulating shares. The company has no near-term profits but has a strong cash position and strategic partnerships.

Recursion Pharmaceuticals (RXRX) stock rose 3.85% on news of a Sanofi partnership and ARK Investment's purchases. The company reported positive clinical data for REC-4881 and REC-1245, and raised $200M in equity. RXRX has a strong cash position and a runway into 2029, but remains unprofitable with negative margins.

Recursion (RXRX) reported positive results from its Phase 1b/2 trial of REC-4881, showing an 87% mean reduction in GI polyp burden and a 92% reduction in upper GI. The drug demonstrated a favorable safety profile, with no treatment-related adverse events above Grade 3. The company plans a registrational trial in H2 2027, pending FDA discussions. Recursion had $561M in cash as of Sept 30, 2026, and expects $200M from a recent offering, extending its runway into 2029.

Recursion Pharmaceuticals (RXRX) shares surged 17.9% after Sanofi initiated development of drug molecules, triggering a $10M milestone payment, totaling $144M received. RXRX may earn over $300M more in milestones and royalties if approved. The collaboration, started in 2022, focuses on AI-enabled small molecule therapies in immunology and oncology. Hedge fund holdings in RXRX increased 16% QoQ to $287.9M, despite a drop in the number of funds invested.

Recursion Pharmaceuticals (RXRX) rose 14.4% after Sanofi exercised an option on a collaboration candidate, triggering a $10M milestone. The company also announced a $200M financing and positive clinical data for REC-4881 and REC-1245. Sanofi's option ends Recursion's operational requirements for the candidate.